Cargando…

Combined Radionuclide Therapy and Immunotherapy for Treatment of Triple Negative Breast Cancer

Triple negative breast cancer (TNBC) is an aggressive subtype of the disease with poor clinical outcomes and limited therapeutic options. Immune checkpoint blockade (CP) has surged to the forefront of cancer therapies with widespread clinical success in a variety of cancer types. However, the percen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vito, Alyssa, Rathmann, Stephanie, Mercanti, Natalie, El-Sayes, Nader, Mossman, Karen, Valliant, John
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8124136/ https://www.ncbi.nlm.nih.gov/pubmed/34063642 http://dx.doi.org/10.3390/ijms22094843

Ejemplares similares

Tumor Heterogeneity: A Great Barrier in the Age of Cancer Immunotherapy
por: El-Sayes, Nader, et al.
Publicado: (2021)

Response to FEC Chemotherapy and Oncolytic HSV-1 Is Associated with Macrophage Polarization and Increased Expression of S100A8/A9 in Triple Negative Breast Cancer
por: Vito, Alyssa, et al.
Publicado: (2021)

Hypoxia-Driven Immune Escape in the Tumor Microenvironment
por: Vito, Alyssa, et al.
Publicado: (2020)

A Combination of Chemotherapy and Oncolytic Virotherapy Sensitizes Colorectal Adenocarcinoma to Immune Checkpoint Inhibitors in a cDC1-Dependent Manner
por: El-Sayes, Nader, et al.
Publicado: (2022)

Immune checkpoint blockade in triple negative breast cancer influenced by B cells through myeloid-derived suppressor cells
por: Vito, Alyssa, et al.
Publicado: (2021)

IFNAR blockade synergizes with oncolytic VSV to prevent virus-mediated PD-L1 expression and promote antitumor T cell activity
por: El-Sayes, Nader, et al.
Publicado: (2022)

Mechanisms of PD-L1 Regulation in Malignant and Virus-Infected Cells
por: Farrukh, Hadia, et al.
Publicado: (2021)

Combination Therapies to Improve the Efficacy of Immunotherapy in Triple-negative Breast Cancer
por: Alečković, Maša, et al.
Publicado: (2023)

Immunotherapy for Triple-Negative Breast Cancer
por: Cao, Yifeng, et al.
Publicado: (2021)

Immunotherapy for Triple-Negative Breast Cancer: Combination Strategies to Improve Outcome
por: Li, Liying, et al.
Publicado: (2023)

Oncolytic BHV-1 Is Sufficient to Induce Immunogenic Cell Death and Synergizes with Low-Dose Chemotherapy to Dampen Immunosuppressive T Regulatory Cells
por: Davola, Maria Eugenia, et al.
Publicado: (2023)

Developments in Combining Targeted Radionuclide Therapies and Immunotherapies for Cancer Treatment
por: Kerr, Caroline P., et al.
Publicado: (2022)

Immunotherapy Treatment for Triple Negative Breast Cancer
por: Berger, Elizabeth R., et al.
Publicado: (2021)

Prospects of Immunotherapy for Triple-Negative Breast Cancer
por: Qiu, Dan, et al.
Publicado: (2022)

Immunotherapy for the Treatment of Triple-Negative Breast Cancer
por: Tolaney, Sara M., et al.
Publicado: (2022)

Advances in immunotherapy for triple-negative breast cancer
por: Liu, Yang, et al.
Publicado: (2023)

Current Progresses and Challenges of Immunotherapy in Triple-Negative Breast Cancer
por: Mediratta, Karan, et al.
Publicado: (2020)

Triple-negative breast cancer and radiation therapy
por: de Faria Bessa, Jordana, et al.
Publicado: (2022)

The clinical promise of immunotherapy in triple-negative breast cancer
por: Vikas, Praveen, et al.
Publicado: (2018)

Modern Immunotherapy in the Treatment of Triple-Negative Breast Cancer
por: Wesolowski, Jakub, et al.
Publicado: (2022)

Clinical trials of immunotherapy in triple-negative breast cancer
por: Howard, Frederick M., et al.
Publicado: (2022)

Progress and Prospect of Immunotherapy for Triple-Negative Breast Cancer
por: Luo, Chenyi, et al.
Publicado: (2022)

Correction: Advances in immunotherapy for triple-negative breast cancer
por: Liu, Yang, et al.
Publicado: (2023)

Enhanced Therapeutic Efficacy of Combining Losartan and Chemo-Immunotherapy for Triple Negative Breast Cancer
por: Zhao, Qing, et al.
Publicado: (2022)

(177)Lu-NM600 Targeted Radionuclide Therapy Extends Survival in Syngeneic Murine Models of Triple-Negative Breast Cancer
por: Hernandez, Reinier, et al.
Publicado: (2020)

Molecular Imaging of Oxygenation Changes during Immunotherapy in Combination with Paclitaxel in Triple Negative Breast Cancer
por: Napier, Tiara S., et al.
Publicado: (2023)

Regression and Eradication of Triple-Negative Breast Carcinoma in 4T1 Mouse Model by Combination Immunotherapies
por: Nahar, Saifun, et al.
Publicado: (2023)

HDAC inhibition potentiates immunotherapy in triple negative breast cancer
por: Terranova-Barberio, Manuela, et al.
Publicado: (2017)

Recent advances in triple negative breast cancer: the immunotherapy era
por: Marra, Antonio, et al.
Publicado: (2019)

Epigenetic Regulation of Immunotherapy Response in Triple-Negative Breast Cancer
por: Llinàs-Arias, Pere, et al.
Publicado: (2021)

Research progress on immunotherapy in triple-negative breast cancer (Review)
por: Zhang, Xiaoxiao, et al.
Publicado: (2022)

Immunotherapy in triple negative breast cancer: beyond checkpoint inhibitors
por: Abdou, Yara, et al.
Publicado: (2022)

Triple negative breast cancer: Immunogenicity, tumor microenvironment, and immunotherapy
por: Loizides, Sotiris, et al.
Publicado: (2023)

Hope and Hype around Immunotherapy in Triple-Negative Breast Cancer
por: Jacobs, Flavia, et al.
Publicado: (2023)

Molecular mechanisms of immunotherapy resistance in triple-negative breast cancer
por: Zheng, Yiwen, et al.
Publicado: (2023)

Spatial predictors of immunotherapy response in triple-negative breast cancer
por: Wang, Xiao Qian, et al.
Publicado: (2023)

Neoadjuvant immunotherapy in early-stage triple negative breast cancer
por: Laouris, Panayiotis, et al.
Publicado: (2023)

Therapeutic progress and challenges for triple negative breast cancer: targeted therapy and immunotherapy
por: Yang, Ruoning, et al.
Publicado: (2022)

Combination Therapy, a Promising Approach to Enhance the Efficacy of Radionuclide and Targeted Radionuclide Therapy of Prostate and Breast Cancer
por: Damiana, Tyrillshall S. T., et al.
Publicado: (2021)

Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies
por: Ashraf, Yahya, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_21ghrfmhljsp05t7ujte27oajt